Skip to content
HowShorted

CytomX Therapeutics, Inc. short interest in 2020

In 2020, CytomX Therapeutics, Inc.'s disclosed short interest ran from 3.39% of shares outstanding on 15 Jan 2020 to 6.27% on 31 Dec 2020, a change of +2.88 percentage points. The year's high was 8.55% on 30 Oct 2020 and its low 1.90% on 31 Mar 2020, averaging 5.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.38 days on 15 Oct 2020. Full history: CytomX Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CytomX Therapeutics, Inc. in 2020

2020 in figures

Start of year
3.39% (15 Jan 2020)
End of year
6.27% (31 Dec 2020)
Change
+2.88 pp
High
8.55% (30 Oct 2020)
Low
1.90% (31 Mar 2020)
Average
5.11%
Highest days to cover
12.38 (15 Oct 2020)
SEC filings marked
8

Every report in 2020

CytomX Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20203.39%5.05
31 Jan 20202.88%4.08
14 Feb 20202.54%3.69
28 Feb 20202.80%2.4710-K filed, results (8-K)
13 Mar 20203.12%3.06
31 Mar 20201.90%1.74
15 Apr 20202.74%2.89
30 Apr 20202.33%2.16
15 May 20202.56%1.3210-Q filed, results (8-K)
29 May 20202.61%1.84
15 Jun 20203.67%2.65
30 Jun 20206.91%4.79
15 Jul 20205.81%6.98
31 Jul 20206.98%8.43
14 Aug 20207.19%9.3810-Q filed, results (8-K)
31 Aug 20207.61%11.06
15 Sep 20207.15%6.56
30 Sep 20206.64%7.76
15 Oct 20207.36%12.38
30 Oct 20208.55%9.57
13 Nov 20207.93%10.2110-Q filed, results (8-K)
30 Nov 20207.12%11.18
15 Dec 20206.50%6.17
31 Dec 20206.27%4.34

See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.